235 related articles for article (PubMed ID: 25897259)
1. The current and future state of companion diagnostics.
Agarwal A; Ressler D; Snyder G
Pharmgenomics Pers Med; 2015; 8():99-110. PubMed ID: 25897259
[TBL] [Abstract][Full Text] [Related]
2. The Regulation of Companion Diagnostics: A Global Perspective.
Ansari M
Ther Innov Regul Sci; 2013 Jul; 47(4):405-415. PubMed ID: 30235516
[TBL] [Abstract][Full Text] [Related]
3. Do companion diagnostics make economic sense for drug developers?
Agarwal A
N Biotechnol; 2012 Sep; 29(6):695-708. PubMed ID: 22575210
[TBL] [Abstract][Full Text] [Related]
4. A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics.
Luo D; Smith JA; Meadows NA; Schuh A; Manescu KE; Bure K; Davies B; Horne R; Kope M; DiGiusto DL; Brindley DA
Front Genet; 2015; 6():357. PubMed ID: 26858745
[TBL] [Abstract][Full Text] [Related]
5. Update on molecular companion diagnostics - a future in personalized medicine beyond Sanger sequencing.
Campbell MR
Expert Rev Mol Diagn; 2020 Jun; 20(6):637-644. PubMed ID: 32167388
[TBL] [Abstract][Full Text] [Related]
6. Clinical and economic challenges facing pharmacogenomics.
Cohen J; Wilson A; Manzolillo K
Pharmacogenomics J; 2013 Aug; 13(4):378-88. PubMed ID: 22231566
[TBL] [Abstract][Full Text] [Related]
7. [Current situation and challenges in companion diagnostics development].
Nishida M
Gan To Kagaku Ryoho; 2014 Dec; 41(13):2529-34. PubMed ID: 25596043
[TBL] [Abstract][Full Text] [Related]
8. Best practices for companion diagnostic and therapeutic development: translating between the stakeholders.
Love D; Stratton E; Stocum M
N Biotechnol; 2012 Sep; 29(6):689-94. PubMed ID: 22743138
[TBL] [Abstract][Full Text] [Related]
9. Aligning the economic value of companion diagnostics and stratified medicines.
Blair ED; Stratton EK; Kaufmann M
J Pers Med; 2012 Nov; 2(4):257-66. PubMed ID: 25562363
[TBL] [Abstract][Full Text] [Related]
10. The clinical benefits, ethics, and economics of stratified medicine and companion diagnostics.
Trusheim MR; Berndt ER
Drug Discov Today; 2015 Dec; 20(12):1439-50. PubMed ID: 26542060
[TBL] [Abstract][Full Text] [Related]
11. Overcoming regulatory and economic challenges facing pharmacogenomics.
Cohen JP
N Biotechnol; 2012 Sep; 29(6):751-6. PubMed ID: 22370122
[TBL] [Abstract][Full Text] [Related]
12. Companion diagnostics and molecular imaging-enhanced approaches for oncology clinical trials.
Van Heertum RL; Scarimbolo R; Ford R; Berdougo E; O'Neal M
Drug Des Devel Ther; 2015; 9():5215-23. PubMed ID: 26392755
[TBL] [Abstract][Full Text] [Related]
13. Companion diagnostics: a regulatory perspective from the last 5 years of molecular companion diagnostic approvals.
Roscoe DM; Hu YF; Philip R
Expert Rev Mol Diagn; 2015; 15(7):869-80. PubMed ID: 26109316
[TBL] [Abstract][Full Text] [Related]
14. Conference Scene: Personalized Medicine in Europe.
Greenberg T
Per Med; 2011 May; 8(3):317-319. PubMed ID: 29783529
[TBL] [Abstract][Full Text] [Related]
15. Challenges in the codevelopment of companion diagnostics.
Moore MW; Babu D; Cotter PD
Per Med; 2012 Jul; 9(5):485-496. PubMed ID: 29768776
[TBL] [Abstract][Full Text] [Related]
16. Current Trends in Personalized Medicine and Companion Diagnostics: A Summary From the DIA Meeting on Personalized Medicine and Companion Diagnostics.
Tsourounis M; Stuart J; Pignato W; Toscani M; Barone J
Ther Innov Regul Sci; 2015 Jul; 49(4):530-543. PubMed ID: 30222427
[TBL] [Abstract][Full Text] [Related]
17. Using companion and coupled diagnostics within strategy to personalize targeted medicines.
Singer DR; Watkins J
Per Med; 2012 Sep; 9(7):751-761. PubMed ID: 29776269
[TBL] [Abstract][Full Text] [Related]
18. Impact of molecular medicine on healthcare markets and strategies for success.
Miller PS; Batchelder KF
Per Med; 2009 Sep; 6(5):529-542. PubMed ID: 29783311
[TBL] [Abstract][Full Text] [Related]
19. Complementary versus companion diagnostics: apples and oranges?
Milne CP; Bryan C; Garafalo S; McKiernan M
Biomark Med; 2015; 9(1):25-34. PubMed ID: 25605453
[TBL] [Abstract][Full Text] [Related]
20. Intellectual property considerations for molecular diagnostic development with emphasis on companion diagnostics.
Glorikian H; Warburg RJ; Moore K; Malinowski J
Expert Opin Ther Pat; 2018 Feb; 28(2):123-128. PubMed ID: 29224409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
